As AI con­tin­ues to en­tice Big Phar­ma, a Car­lyle-led drug­mak­er syn­di­cate shells out $430M for cloud com­put­ing play­er

4 years ago
Financing
Deals

Ven­tyx sprints to Wall Street less than a year af­ter emerg­ing from stealth

4 years ago
Financing

Bris­tol My­ers pledges to sell its Ac­celeron shares as ac­tivist in­vestors cir­cle Mer­ck­'s $11.5B buy­out — re­port

4 years ago
Deals
Pharma

Ep­i­darex, Sofinno­va dou­ble down on a par­al­lel take on 3rd-gen CAR-T — aim­ing straight at ovar­i­an can­cer

4 years ago
Financing
Cell/Gene Tx

Boost­er bo­nan­za: FDA en­dors­es 'mix-and-match' scheme, and Mod­er­na and J&J too

4 years ago
Coronavirus

Hedge fund jumps in with Avoro ac­tivists in an at­tempt to de­rail Mer­ck­'s $11B Ac­celeron buy­out

4 years ago
Deals

Covid-19 roundup: Biden plans for ear­ly No­vem­ber roll­out of vac­cines for kids; EMA eval­u­ates Re­gen­eron's an­ti­body ...

4 years ago
Coronavirus

'No ex­cuse': ICER de­ter­mines As­traZeneca's new mon­ey­mak­er Soliris is vast­ly over­priced

4 years ago
Deals
Pharma

J&J dives deep­er in­to bis­pecifics; Spring­Works an­nounces re­search deal over Stan­ford pro­fes­sor's work

4 years ago
News Briefing

FDA slaps As­traZeneca's MCL-1 can­cer drug with a hold af­ter safe­ty is­sue — 2 years af­ter Am­gen axed a trou­bled ...

4 years ago
R&D
FDA+

FDA shoots down a biotech’s last-stand pa­tient pitch af­ter fault­ing da­ta

4 years ago
FDA+

Ra­dius rock­ets high­er as Kel­ly Mar­tin boasts of a big PhI­II suc­cess — but the spoils be­long to Menar­i­ni

4 years ago
R&D

Some can­cer pa­tients now have to find oth­er op­tions as Bris­tol My­er­s' Abrax­ane falls in­to short­age from man­u­fac­tur­ing ...

4 years ago
Pharma
Manufacturing

A new Schrödinger-backed start­up emerges from the sci­en­tist who mapped the first hu­man GPCR

4 years ago
Financing
Startups

Carl June lends 'wings' to Chi­nese CAR-T start­up led by for­mer post­doc, pur­su­ing off-the-shelf ap­proach with CRISPR ...

4 years ago
People
Cell/Gene Tx

Man­u­fac­tur­ing woes for No­vavax’s Covid jab bad­ly dis­rupt plans for roll­out to the poor — re­port

4 years ago
Coronavirus
Manufacturing

Sur­geons suc­cess­ful­ly at­tach pig kid­ney to a hu­man for the first time, us­ing tech from Unit­ed's Re­vivi­cor

4 years ago
R&D
Discovery

Up­dat­ed: Bio­gen sells just $300K worth of Aduhelm in Q3, as ques­tions on long-term vi­a­bil­i­ty re­main

4 years ago
Pharma

Gates Foun­da­tion pledges $120M to ramp up gener­ic sup­ply of Mer­ck­'s Covid-19 pill while ac­tivists blast Pfiz­er's ...

4 years ago
Coronavirus

Renowned Dana-Far­ber sci­en­tist, men­tor and bio­phar­ma ad­vi­sor David Liv­ingston has died

4 years ago
People

Sage, Bio­gen head to FDA with $3.1B de­pres­sion drug; Sana puts down $50M to tap Beam's CRISPR tech

4 years ago
News Briefing

FDA warns Min­neso­ta doc for run­ning two ke­t­a­mine tri­als with­out INDs, and with chil­dren and a preg­nant woman

4 years ago
FDA+

No­vo CEO Lars Fruer­gaard Jør­gensen on R&D risk, the deal strat­e­gy and tar­gets for gen­der di­ver­si­ty

4 years ago
R&D

As­traZeneca's for­mer an­tibi­otics unit claims a PhI­II win in drug-re­sis­tant bac­te­ria af­fect­ing sick­ly pa­tients

4 years ago
R&D
First page Previous page 634635636637638639640 Next page Last page
A service from the Financial Times